ULTRAGENYX PHARMACEUTICAL INC. Stock-Based Compensation
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Stock-Based Compensation of $34.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $34.00M, a 12.82% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $30.00K, a 25.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $37.47M, a 6.65% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $37.01M, a 10.97% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, expense for fiscal 2025 was $153.00M, a 3.16% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, expense for fiscal 2024 was $158.00M, a 17.04% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, expense for fiscal 2023 was $135.00M, a 3.55% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, expense for fiscal 2022 was $130.37M, a 24.18% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed | Share-based Payment Arrangement, Expense 47 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $34.00M 10-Q · filed 2026-08-05 | $64.00M 10-Q · filed 2026-08-05 | $71.50M derived: sum of 3 quarters · filed 2026-08-05 | $108.50M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $30.00K 10-Q · filed 2026-05-06 | $37.49M derived: sum of 2 quarters · filed 2026-05-06 | $74.50M derived: sum of 3 quarters · filed 2026-05-06 | $113.50M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $37.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $74.47M derived: sum of 2 quarters · filed 2026-02-18 | $113.47M derived: sum of 3 quarters · filed 2026-08-05 | $153.00M 10-K · filed 2026-02-18 | ||||
| 2025-09-30 | $37.01M 10-Q · filed 2025-11-05 | $76.01M derived: sum of 2 quarters · filed 2026-08-05 | $115.53M 10-Q · filed 2025-11-05 | $116.18M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $39.00M 10-Q · filed 2026-08-05 | $38.62M 10-Q · filed 2025-08-06 | $79.00M 10-Q · filed 2026-08-05 | $78.53M 10-Q · filed 2025-08-06 | $79.17M derived: sum of 3 quarters · filed 2026-08-05 | $120.74M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $40.00K 10-Q · filed 2026-05-06 | $39.91M 10-Q · filed 2025-05-07 | $40.17M derived: sum of 2 quarters · filed 2026-05-06 | $81.74M derived: sum of 3 quarters · filed 2026-05-06 | $121.11M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $40.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $81.70M derived: sum of 2 quarters · filed 2026-02-18 | $121.07M derived: sum of 3 quarters · filed 2026-02-18 | $158.00M 10-K · filed 2026-02-18 | $158.06M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $41.57M 10-Q · filed 2025-11-05 | $80.93M derived: sum of 2 quarters · filed 2025-11-05 | $117.87M 10-Q · filed 2025-11-05 | $151.40M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-06-30 | $39.36M 10-Q · filed 2025-08-06 | $76.30M 10-Q · filed 2025-08-06 | $109.83M derived: sum of 3 quarters · filed 2026-02-18 | $144.71M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-03-31 | $36.93M 10-Q · filed 2025-05-07 | $70.47M derived: sum of 2 quarters · filed 2026-02-18 | $105.34M derived: sum of 3 quarters · filed 2026-02-18 | $140.00M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2023-12-31 | $33.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $68.41M derived: sum of 2 quarters · filed 2026-02-18 | $103.06M derived: sum of 3 quarters · filed 2026-02-18 | $135.00M 10-K · filed 2026-02-18 | $135.21M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $34.88M 10-Q · filed 2024-11-06 | $69.53M derived: sum of 2 quarters · filed 2024-11-06 | $101.47M 10-Q · filed 2024-11-06 | $130.82M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $34.65M 10-Q · filed 2024-08-02 | $66.59M 10-Q · filed 2024-08-02 | $95.95M derived: sum of 3 quarters · filed 2025-02-19 | $131.71M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $31.94M 10-Q · filed 2024-05-03 | $61.29M derived: sum of 2 quarters · filed 2025-02-19 | $97.06M derived: sum of 3 quarters · filed 2025-02-19 | $132.92M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $29.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $65.12M derived: sum of 2 quarters · filed 2025-02-19 | $100.98M derived: sum of 3 quarters · filed 2025-02-19 | $130.37M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | $35.76M 10-Q · filed 2023-11-03 | $71.63M derived: sum of 2 quarters · filed 2023-11-03 | $101.01M 10-Q · filed 2023-11-03 | $127.56M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $35.87M 10-Q · filed 2023-08-04 | $65.25M 10-Q · filed 2023-08-04 | $91.80M derived: sum of 3 quarters · filed 2024-02-21 | $118.79M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $29.39M 10-Q · filed 2023-05-05 | $55.94M derived: sum of 2 quarters · filed 2024-02-21 | $82.93M derived: sum of 3 quarters · filed 2024-02-21 | $110.07M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $26.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $53.54M derived: sum of 2 quarters · filed 2024-02-21 | $80.68M derived: sum of 3 quarters · filed 2024-02-21 | $104.98M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $26.99M 10-Q · filed 2022-11-03 | $54.13M derived: sum of 2 quarters · filed 2022-11-03 | $78.43M 10-Q · filed 2022-11-03 | $101.24M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | $27.14M 10-Q · filed 2022-07-29 | $51.44M 10-Q · filed 2022-07-29 | $74.25M derived: sum of 3 quarters · filed 2023-02-17 | $94.59M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $24.30M 10-Q · filed 2022-05-06 | $47.11M derived: sum of 2 quarters · filed 2023-02-17 | $67.45M derived: sum of 3 quarters · filed 2023-02-17 | $89.86M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | $22.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $43.15M derived: sum of 2 quarters · filed 2023-02-17 | $65.56M derived: sum of 3 quarters · filed 2023-02-17 | $85.73M 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $20.34M 10-Q · filed 2021-11-03 | $42.75M derived: sum of 2 quarters · filed 2021-11-03 | $62.92M 10-Q · filed 2021-11-03 | $82.58M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-06-30 | $22.41M 10-Q · filed 2021-08-03 | $42.58M 10-Q · filed 2021-08-03 | $62.24M derived: sum of 3 quarters · filed 2022-02-15 | $82.15M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-03-31 | $20.17M 10-Q · filed 2021-05-05 | $39.83M derived: sum of 2 quarters · filed 2022-02-15 | $59.74M derived: sum of 3 quarters · filed 2022-02-15 | $81.95M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2019-12-31 | $19.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $39.57M derived: sum of 2 quarters · filed 2022-02-15 | $61.77M derived: sum of 3 quarters · filed 2022-02-15 | $82.00M 10-K · filed 2022-02-15 | ||||
| 2019-09-30 | $19.91M 10-Q · filed 2020-10-27 | $42.11M derived: sum of 2 quarters · filed 2020-10-27 | $62.34M 10-Q · filed 2020-10-27 | $83.42M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-06-30 | $22.21M 10-Q · filed 2020-07-30 | $42.43M 10-Q · filed 2020-07-30 | $63.51M derived: sum of 3 quarters · filed 2021-02-12 | $84.17M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-03-31 | $20.22M 10-Q · filed 2020-05-07 | $41.30M derived: sum of 2 quarters · filed 2021-02-12 | $61.97M derived: sum of 3 quarters · filed 2021-02-12 | $81.53M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2018-12-31 | $21.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $41.75M derived: sum of 2 quarters · filed 2021-02-12 | $61.31M derived: sum of 3 quarters · filed 2021-02-12 | $80.11M 10-K · filed 2021-02-12 | ||||
| 2018-09-30 | $20.67M 10-Q · filed 2019-11-06 | $40.23M derived: sum of 2 quarters · filed 2019-11-06 | $59.03M 10-Q · filed 2019-11-06 | $78.57M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-06-30 | $19.56M 10-Q · filed 2019-08-02 | $38.36M 10-Q · filed 2019-08-02 | $57.90M derived: sum of 3 quarters · filed 2020-02-14 | $75.08M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2018-03-31 | $18.80M 10-Q · filed 2019-05-07 | $38.34M derived: sum of 2 quarters · filed 2020-02-14 | $55.52M derived: sum of 3 quarters · filed 2020-02-14 | $72.31M derived: sum of 4 quarters · filed 2020-02-14 | ||||
| 2017-12-31 | $19.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $36.72M derived: sum of 2 quarters · filed 2020-02-14 | $53.52M derived: sum of 3 quarters · filed 2020-02-14 | $68.01M 10-K · filed 2020-02-14 | ||||
| 2017-09-30 | $17.18M 10-Q · filed 2018-11-06 | $33.97M derived: sum of 2 quarters · filed 2018-11-06 | $48.47M 10-Q · filed 2018-11-06 | $62.01M derived: sum of 4 quarters · filed 2019-02-20 | ||||
| 2017-06-30 | $16.79M 10-Q · filed 2018-08-03 | $31.29M 10-Q · filed 2018-08-03 | $44.83M derived: sum of 3 quarters · filed 2019-02-20 | $58.52M derived: sum of 4 quarters · filed 2019-02-20 | ||||
| 2017-03-31 | $14.50M 10-Q · filed 2018-05-08 | $28.04M derived: sum of 2 quarters · filed 2019-02-20 | $41.73M derived: sum of 3 quarters · filed 2019-02-20 | $52.59M derived: sum of 4 quarters · filed 2019-02-20 | ||||
| 2016-12-31 | $13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $27.23M derived: sum of 2 quarters · filed 2019-02-20 | $38.09M derived: sum of 3 quarters · filed 2019-02-20 | $48.31M 10-K · filed 2019-02-20 | ||||
| 2016-09-30 | $13.69M 10-Q · filed 2017-11-03 | $24.55M derived: sum of 2 quarters · filed 2017-11-03 | $34.77M 10-Q · filed 2017-11-03 | $44.26M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $10.86M 10-Q · filed 2017-07-28 | $21.08M 10-Q · filed 2017-07-28 | $30.57M derived: sum of 3 quarters · filed 2018-02-21 | $38.46M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $10.22M 10-Q · filed 2017-05-05 | $19.71M derived: sum of 2 quarters · filed 2018-02-21 | $27.60M derived: sum of 3 quarters · filed 2018-02-21 | $32.69M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $9.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $17.39M derived: sum of 2 quarters · filed 2018-02-21 | $22.48M derived: sum of 3 quarters · filed 2018-02-21 | $24.88M 10-K · filed 2018-02-21 | ||||
| 2015-09-30 | $7.90M 10-Q · filed 2016-11-08 | $12.99M derived: sum of 2 quarters · filed 2016-11-08 | $15.39M 10-Q · filed 2016-11-08 | $17.40M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $5.09M 10-Q · filed 2016-08-09 | $7.50M 10-Q · filed 2016-08-09 | $9.50M derived: sum of 3 quarters · filed 2017-02-17 | $11.15M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $2.41M 10-Q · filed 2016-05-10 | $4.41M derived: sum of 2 quarters · filed 2017-02-17 | $6.06M derived: sum of 3 quarters · filed 2017-02-17 | $7.01M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $3.65M derived: sum of 2 quarters · filed 2017-02-17 | $4.60M derived: sum of 3 quarters · filed 2017-02-17 | $5.39M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $1.65M 10-Q · filed 2015-11-10 | $2.60M derived: sum of 2 quarters · filed 2015-11-10 | $3.39M 10-Q · filed 2015-11-10 | $3.60M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-06-30 | $946.00K 10-Q · filed 2015-08-14 | $1.74M 10-Q · filed 2015-08-14 | $1.95M derived: sum of 3 quarters · filed 2016-02-26 | $2.02M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-03-31 | $795.00K 10-Q · filed 2015-05-12 | $1.00M derived: sum of 2 quarters · filed 2016-02-26 | $1.08M derived: sum of 3 quarters · filed 2016-02-26 | $1.26M derived: sum of 4 quarters · filed 2016-02-26 | $2.60M 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $281.00K derived: sum of 2 quarters · filed 2016-02-26 | $466.00K derived: sum of 3 quarters · filed 2016-02-26 | $657.00K 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | $71.00K 10-Q · filed 2014-11-10 | $256.00K derived: sum of 2 quarters · filed 2014-11-10 | $447.00K 10-Q · filed 2014-11-10 | |||||
| 2013-06-30 | $185.00K 10-Q · filed 2014-08-11 | $376.00K 10-Q · filed 2014-08-11 | ||||||
| 2013-03-31 | $191.00K 10-Q · filed 2014-05-12 | |||||||
| 2012-12-31 | $891.00K 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |